From GlobeNewswire:

Axial Therapeutics, a biotechnology company, will feature its CEO Dr. A. Stewart Campbell at the 2024 Biotech Showcase. They specialize in developing gut-targeted small molecule therapeutics for neurological and oncology purposes. The company is known for its work in elucidating the role of the microbiome-gut-brain axis. Currently, its lead product candidate is AB-2004 used in clinical trials for treating irritability in children with autism. For more information, visit their website at https://axialtx.com. Contacts include Maura Gavaghan for media and Jeffrey Young for investors, who can be reached at [email protected] and [email protected], respectively.



Read more: Axial Therapeutics to Present at Upcoming Conferences